bevacizumab,panitumumab
igm biosciences,roche,takeda,amgen
['biomarker', ' bev ', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'pani ', 'igm bio']
dr. yamazaki w/ paradigm biomarker study: 1l l-sided ras wt mcrc treated with folfox and either bev or pani. looked at mutations based on ctdna. pani better in mss/msi-l ras/braf wt group but not better (maybe worse) in msi-h or ras/braf mt group. #asco23 
Medical oncologist: GI cancers & cancer of unknown primary + high quality & value-based cancer care delivery. @UTexasValue MSHCT student. Tweets mine.